Quantum Biopharma (QNTM) Liabilities and Shareholders Equity (2021 - 2026)

Quantum Biopharma's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.35% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $55.5 million (down 16.19% YoY), while the FY2025 annual figure was $11.2 million, down 34.8% from the prior year.
• Liabilities and Shareholders Equity came in at $14.9 million for Q1 2026 at Quantum Biopharma, up from $11.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $38.4 million in Q4 2022 to a low of $11.2 million in Q4 2025.
• A 5-year average of $17.8 million and a median of $15.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 54.51% in 2023 and grew 0.35% in 2026, its largest moves.
• Quantum Biopharma's Liabilities and Shareholders Equity stood at $38.4 million in 2022, then tumbled by 54.51% to $17.5 million in 2023, then dropped by 2.03% to $17.1 million in 2024, then sank by 34.8% to $11.2 million in 2025, then surged by 33.74% to $14.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $14.9 million, $11.2 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison